Advanced Solid Tumor, Breast Cancer, HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Metastatic Solid Tumor
Conditions
Keywords
advanced solid tumor, metastatic solid tumor, BGB-43395, breast cancer, HR+/HER2- breast cancer, hormone receptor positive breast cancer
Brief summary
This is an open-label, multicenter, phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, as monotherapy or in combination with fulvestrant, letrozole, or other combination partners in Chinese participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced or metastatic solid tumors.
Detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Interventions
DRUGBGB-43395
Administered orally.
DRUGFulvestrant
Administered via intramuscular injection.
DRUGLetrozole
Administered orally.
Sponsors
BeOne Medicines
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Phase 1a (Dose Escalation): Participants with histologically or cytologically confirmed locally advanced or metastatic solid tumors associated with CDK4 dependency, including HR+/HER2- breast cancer. Participants must have received prior standard-of-care therapies for their disease, unless the therapy is not available or not tolerated, or is determined not appropriate based on the investigator's judgment. * Phase 1b (Dose Expansion): Participants with selected solid tumors including locally advanced or metastatic HR+/HER2- breast cancer. * Female participants with metastatic HR+/HER2- breast cancer will be required to have ovarian function suppression using gonadotropin-releasing hormone (GnRH) agonists such as goserelin or be postmenopausal. * Male participants with HR+/HER2- breast cancer will be required to have gonadal suppression using GnRH agonists when being treated with letrozole or fulvestrant. * Patients must have ≥1 measurable lesion per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1. * Adequate organ function without symptomatic visceral disease.
Exclusion criteria
* Prior therapy selectively targeting CDK4 (prior CDK4/6 inhibitor therapy is permitted). * Known leptomeningeal disease or uncontrolled untreated brain metastasis. * Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast). * Uncontrolled diabetes. * Infection requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection. Patients receiving prophylactic antibiotics (eg, for prevention of urinary tract infection, chronic obstructive pulmonary disease, or for dental extraction) are eligible. Patients who have recovered from symptomatic COVID-19 infection can be rescreened for this study. * Untreated chronic hepatitis B or active hepatitis C infection. Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to approximately 30 months | Number of participants with AEs and SAEs including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments as needed, and that meet protocol-defined dose-limiting toxicity (DLT) criteria. |
| Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395 | Up to approximately 30 months | MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached. |
| Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-43395 | Up to approximately 30 months | RDFE of BGB-43395 alone or as part of combination therapies will be determined based upon the MTD or MAD. |
| Phase 1b: Objective Response Rate (ORR) | Up to approximately 30 months | ORR is defined as the percentage of participants who have confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1a: ORR | Up to approximately 30 months | ORR is defined as the percentage of participants who have confirmed CR or PR assessed by the investigator using RECIST v1.1. |
| Phase 1b: Progression-Free Survival (PFS) | Up to approximately 30 months | PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first. |
| Phase 1b: Number of Participants with AEs and SAEs | Up to approximately 30 months | Number of participants with AEs and SAEs including findings from physical examinations, ECGs, and laboratory assessments as needed. |
| Phase 1a and 1b: Duration of Response (DOR) | Up to approximately 30 months | DOR is defined as the time from the first determination of an objective response by the investigator using RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first. |
| Phase 1a and 1b: Time to Response (TTR) | Up to approximately 30 months | TTR is defined as the time from the date of the first dose of study drugs to the date of the first determination of objective response that is confirmed by a subsequent response as assessed by the investigator using RECIST v1.1. |
| Phase 1b: Disease Control Rate (DCR) | Up to approximately 30 months | DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease assessed by the investigator using RECIST v1.1. |
| Phase 1b: Clinical Benefit Rate (CBR) | Up to approximately 30 months | CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks. |
| Phase 1a: Observed plasma maximum concentration (Cmax) of BGB-43395 and its metabolite | From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days) | — |
| Phase 1a: Observed plasma trough concentration (Ctrough) of BGB-43395 and its metabolite | From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days) | — |
| Phase 1a: Area under the concentration-time curve (AUC) of BGB-43395 and its metabolite | From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days) | — |
| Phase 1a: Half-life (t1/2) of BGB-43395 and its metabolite | From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days) | — |
| Phase 1b: Plasma concentrations of BGB-43395 and its metabolite | From Cycle 1 Day 1 up to Cycle 5 Day 1 (each cycle is 28 days) | — |
Countries
China
Contacts
STUDY_DIRECTORStudy Director
BeOne Medicines
Outcome results
None listed